Insider Transactions in Q1 2023 at Revance Therapeutics, Inc. (RVNC)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2023
|
Dustin S Sjuts President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,967
-2.39%
|
$89,010
$30.65 P/Share
|
|
Mar 15
2023
|
Dwight Moxie CLO & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
7,330
-13.2%
|
$219,900
$30.65 P/Share
|
|
Mar 15
2023
|
Tobin Schilke CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,739
-5.11%
|
$112,170
$30.65 P/Share
|
|
Mar 15
2023
|
Mark J Foley CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,341
-0.65%
|
$160,230
$30.65 P/Share
|
|
Mar 09
2023
|
Mark J Foley CEO |
SELL
Open market or private sale
|
Direct |
70,390
-7.88%
|
$2,182,090
$31.59 P/Share
|
|
Mar 09
2023
|
Dustin S Sjuts President |
SELL
Open market or private sale
|
Direct |
21,508
-14.79%
|
$666,748
$31.59 P/Share
|
|
Mar 09
2023
|
Tobin Schilke CFO |
SELL
Open market or private sale
|
Direct |
18,517
-20.18%
|
$574,027
$31.59 P/Share
|
|
Mar 09
2023
|
Dwight Moxie CLO & GC |
SELL
Open market or private sale
|
Direct |
18,496
-24.98%
|
$573,376
$31.59 P/Share
|
|
Mar 01
2023
|
Vlad Coric Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,195
+50.0%
|
-
|
|
Mar 01
2023
|
Tobin Schilke CFO |
SELL
Open market or private sale
|
Direct |
3,201
-6.09%
|
$105,633
$33.5 P/Share
|
|
Feb 15
2023
|
Tobin Schilke CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,085
-3.81%
|
$68,805
$33.21 P/Share
|
|
Feb 15
2023
|
Dustin S Sjuts President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,766
-2.89%
|
$91,278
$33.21 P/Share
|
|
Feb 01
2023
|
Tobin Schilke CFO |
SELL
Open market or private sale
|
Direct |
3,201
-5.53%
|
$108,834
$34.6 P/Share
|
|
Jan 20
2023
|
Tobin Schilke CFO |
SELL
Open market or private sale
|
Direct |
1,000
-1.7%
|
$31,000
$31.0 P/Share
|
|
Jan 09
2023
|
Tobin Schilke CFO |
SELL
Open market or private sale
|
Direct |
3,701
-2.01%
|
$99,927
$27.67 P/Share
|